Published in Annu Rev Neurosci on January 01, 1987
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol (2010) 2.60
Hydrogen sulfide as a gasotransmitter. J Neurochem (2010) 2.30
De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry (2013) 1.93
Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci (2008) 1.41
Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther (2010) 1.34
Regulation of monoamine transporters: Role of transporter phosphorylation. Pharmacol Ther (2010) 1.30
Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience (2007) 1.30
Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochem Pharmacol (2006) 1.24
Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci (2010) 1.19
Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. J Neurosci (2012) 1.14
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci (2012) 1.12
Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain (2014) 1.08
Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci (2012) 1.02
Infantile parkinsonism-dystonia: a dopamine "transportopathy". J Clin Invest (2009) 0.88
The dynamics of somatic exocytosis in monoaminergic neurons. Front Physiol (2012) 0.84
Persistent hyperdopaminergia decreases the peak frequency of hippocampal theta oscillations during quiet waking and REM sleep. PLoS One (2009) 0.83
Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour. J Psychiatry Neurosci (2016) 0.77
Understanding the role of serotonin in psychiatric diseases. F1000Res (2017) 0.75
Sequence determinants of the Caenhorhabditis elegans dopamine transporter dictating in vivo axonal export and synaptic localization. Mol Cell Neurosci (2016) 0.75
Dopamine transporter mutant animals: a translational perspective. J Neurogenet (2016) 0.75
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. Clin Pharmacol Ther (2016) 0.75
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med (1997) 3.49
A prospective randomised trial of internal fixation versus arthroplasty for displaced fractures of the neck of the femur. Functional outcome for 450 patients at two years. J Bone Joint Surg Br (2002) 3.40
Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur J Pharmacol (1969) 2.61
Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes (1999) 2.36
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. Eur J Pharmacol (1969) 2.26
The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect (1993) 2.20
The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther (2013) 2.01
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci (1990) 1.91
Modification of sympathetic function. Pharmacological depletion of catecholamine stores. Pharmacol Rev (1966) 1.56
Movement patterns of the C-stem femoral component: an RSA study of 33 primary total hip arthroplasties followed for two years. J Bone Joint Surg Br (2005) 1.53
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med (1993) 1.50
Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol Scand (1967) 1.49
Continuous distal migration and internal rotation of the C-stem prosthesis without any adverse clinical effects: an RSA study of 33 primary total hip arthroplasties followed for up to ten years. Bone Joint J (2014) 1.45
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry (2000) 1.43
Insect immunity. The primary structure of the antibacterial protein attacin F and its relation to two native attacins from Hyalophora cecropia. EMBO J (1984) 1.35
Oral L-dopa treatment of parkinsonism. Acta Med Scand (1970) 1.35
Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines. J Pharm Pharmacol (1969) 1.34
Ammonia synthesis from first-principles calculations. Science (2005) 1.33
Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.31
Long-term follow-up of replacement compared with internal fixation for displaced femoral neck fractures: results at ten years in a randomised study of 450 patients. J Bone Joint Surg Br (2010) 1.30
Histochemical amd biochemical effects of diethyldithiocarbamate on tissue catecholamines. J Pharm Pharmacol (1966) 1.29
Blood pressure course in patients with acute stroke and matched controls. Stroke (1986) 1.28
The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol (1968) 1.21
Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull (1990) 1.20
The antibacterial effect of attacins from the silk moth Hyalophora cecropia is directed against the outer membrane of Escherichia coli. EMBO J (1984) 1.19
Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn Schmiedebergs Arch Pharmacol (1972) 1.19
Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm (1976) 1.18
Bone mass in primary coxarthrosis. Acta Orthop Scand (1979) 1.18
Exposure to toluene: uptake, distribution and elimination in man. Scand J Work Environ Health (1982) 1.17
Does tranexamic acid reduce blood loss in knee arthroplasty? Am J Knee Surg (1995) 1.12
Clinical aspects of osseointegration in joint replacement. A histological study of titanium implants. J Bone Joint Surg Br (1988) 1.12
Adrenergic mechanisms. Annu Rev Pharmacol (1969) 1.11
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm (1989) 1.10
Schizophrenia: from dopamine to glutamate and back. Curr Med Chem (2004) 1.09
Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. Scand J Clin Lab Invest (2008) 1.09
The effect of taurine on motor behaviour, body temperature and monoamine metabolism in rat brain. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.08
Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry (1978) 1.07
Seasonal and circadian monoamine variations in human brains examined post mortem. Acta Psychiatr Scand Suppl (1980) 1.07
Mannose-resistant haemagglutination by Campylobacter pylori. Scand J Infect Dis (1988) 1.05
Gloverin, an antibacterial protein from the immune hemolymph of Hyalophora pupae. Eur J Biochem (1997) 1.04
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem (1981) 1.04
Exposure to toluene: concentration in subcutaneous adipose tissue. Scand J Work Environ Health (1982) 1.04
The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity (2011) 1.04
The effect of hypoxia on monoamine synthesis, levels and metabolism in rat brain. J Neurochem (1973) 1.03
Does dopamine play a role in schizophrenia? Psychol Med (1977) 1.02
Vibration white finger: a follow up study. Br J Ind Med (1987) 1.02
Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol (1972) 1.02
Aseptic loosening of hip prostheses. A histologic and enzyme histochemical study. Clin Orthop Relat Res (1983) 1.01
Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk. Acta Diabetol (2008) 1.01
Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry (1998) 1.01
Effects of antidepressant agents on the synthesis of brain monoamines. J Neural Transm (1978) 1.00
Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol (1994) 1.00
Does dopamine have a role in schizophrenia? Biol Psychiatry (1978) 1.00
Social function after cervical hip fracture. A comparison of hook-pins and total hip replacement in 47 patients. Acta Orthop Scand (1996) 1.00
Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav (1981) 0.99
Very high blood pressure in acute stroke. J Intern Med (1990) 0.99
C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes (2011) 0.98
The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Park Dis Dement Sect (1989) 0.98
Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm (1985) 0.98
In vivo effects of the Ca2+-antagonist nimodipine on dopamine metabolism in mouse brain. J Neural Transm (1986) 0.98
Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl (1972) 0.98
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord (2002) 0.97
Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol (2005) 0.97
Effects of the amphetamine group on intraneuronal brain amines in vivo and in vitro. J Pharm Pharmacol (1965) 0.97
Brain tryptophan hydroxylation: dependence on arterial oxygen tension. Science (1973) 0.97
Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv Biochem Psychopharmacol (1980) 0.97
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int (2006) 0.96
Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia (2008) 0.96
Inhibition of ethanol-induced excitation in mice and rats by -methyl-p-tyrosine. Psychopharmacologia (1972) 0.96
Structural specificity for inhibition of [14C]-5-hydroxytryptamine uptake by cerebral slices. J Pharm Pharmacol (1970) 0.95
3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci (1981) 0.95
Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology (1986) 0.95
3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity. J Med Chem (1981) 0.94
Exposure to methylene chloride. I Its concentration in alveolar air and blood during rest and exercise and its metabolism. Scand J Work Environ Health (1975) 0.93
Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol (1973) 0.93
Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl) (1983) 0.92
The accumulation of [3H]noradrenaline in the adrenergic nerve fibres of reserpine-treated mice. J Pharm Pharmacol (1967) 0.92
Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol (1986) 0.92
Recent studies on the mode of action of antidepressive drugs. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1967) 0.92
Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience (2007) 0.92
Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. Pediatrics (1999) 0.92
The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine in the central nervous system. Biochem Soc Symp (1972) 0.91
Transmission of human T-cell lymphotrophic virus type 1 by a deep-frozen bone allograft. Acta Orthop Scand (1997) 0.91
[Blood loss in Charnley's total hip replacement]. Lakartidningen (1977) 0.91
Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging (1983) 0.91
Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect (1994) 0.90
Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes (2012) 0.90
A regional study of sex differences in rat brain serotonin. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.90
Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings. Eur J Pharmacol (1982) 0.89
Distribution of dopamine in the rat cerebral cortex. J Neural Transm (1976) 0.89
Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry (1976) 0.89
Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol (1976) 0.89
A method for the determination of 3,4-dihydroxyphenylalanine (DOPA) in brain. Naunyn Schmiedebergs Arch Pharmacol (1972) 0.89
In-vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J Neural Transm (1973) 0.88
A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J Neural Transm (1989) 0.88
Total hip replacement with a zirconium oxide ceramic femoral head: a randomised roentgen stereophotogrammetric study. J Bone Joint Surg Br (2005) 0.88
Cost of depression: effect of adherence and treatment response. Eur Psychiatry (2006) 0.87
MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol (1997) 0.87